Cabozantinib Bone Turnover Balance

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for osteoporosis are inadequate in addressing the imbalance in bone turnover, leading to increased fracture risk due to enhanced bone resorption over formation, particularly in postmenopausal women and individuals with cancer or malnutrition.

Innovation Solution

Administration of a therapeutically effective amount of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, known as cabozantinib, to patients at risk, which modulates bone turnover by inhibiting osteoclast differentiation and stimulating osteoblast activity, thereby reducing bone resorption and enhancing bone formation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional osteoporosis treatments are used, then bone resorption is reduced, but bone formation is not sufficiently stimulated, resulting in inadequate bone turnover balance

Engineering Contradiction:

Improvebone turnover balanceVSAvoidbone formation rate

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent changes the pharmacological parameters of osteoporosis treatment by using cabozantinib, a tyrosine kinase inhibitor, which has the unique ability to simultaneously reduce osteoclast-mediated bone resorption and stimulate osteoblast-mediated bone formation. This dual action on opposing bone remodeling processes represents a parameter change in treatment mechanism that achieves better bone turnover balance compared to conventional single-action agents.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If bone resorption is strongly inhibited, then bone loss is reduced, but bone formation remains slower, leading to prolonged remodeling imbalance

Engineering Contradiction:

Improvebone mass preservationVSAvoidremodeling cycle duration

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent applies the principle of continuous useful action by utilizing cabozantinib's sustained dual mechanism that continuously both inhibits osteoclast resorption and stimulates osteoblast formation throughout the remodeling cycle. This continuous dual action prevents periods of unbalanced remodeling and maintains ongoing bone mass preservation without prolonged imbalance, addressing the time loss issue in bone recovery.

Inventive Principle:

Principle #20Continuity of useful action

3Productivity

If osteoblast activity is stimulated, then bone formation increases, but without concurrent resorption inhibition, bone mass gain is limited

Engineering Contradiction:

Improvebone formation rateVSAvoidbone mineral density

Core Design Contradiction:

ProductivityVSQuantity of substance

Solution Approach 1:

The patent merges two previously separate therapeutic actions into a single compound: osteoclast resorption inhibition and osteoblast formation stimulation. By combining these opposing but complementary actions in one agent (cabozantinib), the patent achieves synergistic bone mass accumulation that exceeds what either action could accomplish alone, directly addressing the limitation of bone mass gain when formation is stimulated without resorption control.

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS10166225B2Method for treating osteoporosis

Publication Date: 2019.01.01 EXELIXIS INC

AI summary

This invention is directed to the treatment of osteoporosis using N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.